Back to search results

Patient-Centered Home Care for Black Men with Prostate Cancer

This study is looking at whether a new approach called Patient-Centered Home Care (PCHC) can help reduce differences in care and improve the quality of life for Black men with prostate adenocarcinoma (a common type of prostate cancer). Researchers want to see if PCHC is practical and helpful for these patients. You might be able to join if you are a Black man, 18 or older, with prostate cancer, and are familiar with medical care or are currently receiving or will receive prostate cancer treatment. The main goal is to see if PCHC is feasible over a period of up to 6 months. The current status of this study is unclear.

Study design
This is an observational study with a planned enrollment of 77 men. Participants are assigned to one of two groups.
What's involved
Participants in Group 1 may take part in a focus group, complete questionnaires, and potentially an interview. Participants in Group 2 will complete questionnaires throughout the study.
Compensation
Not stated in the trial record.
Follow-up
The feasibility of Patient-centered Home Care (PCHC) is measured at up to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06470750

Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~77 participants
Updated 2026-01-20 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility of Patient-centered Home Care (PCHC)
Measured over Up to 6 months

Conditions

Prostate Adenocarcinoma

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Florida1

Study leadership

  • Roxana S. Dronca, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

GROUP 1 FOCUS GROUPS:
Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer
GROUP 1 SURVEYS:
Are 18 years of age or older
Have histologic evidence of prostate adenocarcinoma
Are requiring, have required, or will require prostate cancer treatment
Have an understanding of the protocol and its requirements
Are willing to fill in a questionnaire and participate in a focused interview
Are able and willing to sign an informed consent
GROUP 1 INTERVIEWS:
Enrollment in the survey phase of the protocol
GROUP 2:
Are 18 years of age or older
Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
Have histologic evidence of prostate adenocarcinoma
Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel)
Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW)
Have an understanding of the protocol and its requirements
Are able and willing to sign informed consent

Exclusion

GROUP 1 FOCUS GROUPS:
Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system
GROUP 1 SURVEYS:
Do not identify as Black men
Have not been diagnosed with prostate cancer
GROUP 1 INTERVIEWS:
Not enrolled in the survey phase of the protocol
GROUP 2:
Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
Have not been diagnosed with histologic evidence of prostate adenocarcinoma
Are not requiring active standard anti-cancer therapy

What this trial measures

  • Feasibility of Patient-centered Home Care (PCHC)Up to 6 months

    Participants will be asked to fill in a brief questionnaire regarding: patient preference for location of therapy (at the infusion center or in the home); perceived difficulties (isolation, less contact with hospital staff and other patients, feeling less secure with less back-up outside the hospital setting, the possibility of equipment malfunctions and complications in the home setting); and advantages (less travelling to specialized medical facilities, reduced risk of hospital acquired infections or blood clots, the ability to receive treatment in the comfort and security of the home, less disruption to family life, increased feeling of control over treatment and illness). Feasibility will be assessed based on responses to the questionnaire.